Company Information

CIN
Status
Date of Incorporation
07 November 2003
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 September 2023
Paid Up Capital
0
Authorised Capital
0

Directors

Mahima Datla
Mahima Datla
Director/Designated Partner
almost 2 years ago
Basuthkar Jagadeeshwar Rao
Basuthkar Jagadeeshwar Rao
Director/Designated Partner
about 2 years ago
Srinivas Oruganti
Srinivas Oruganti
Director/Designated Partner
over 2 years ago
Venkateswara Prasad Gunupati
Venkateswara Prasad Gunupati
Director/Designated Partner
about 4 years ago
Shakthi Meyyappan Nagappan
Shakthi Meyyappan Nagappan
Director/Designated Partner
over 8 years ago
Satish Reddy Kallam
Satish Reddy Kallam
Director/Designated Partner
about 12 years ago
Javed Iqbal
Javed Iqbal
Wholetime Director
about 13 years ago
Pradeep Chandra Kathi
Pradeep Chandra Kathi
Nominee Director
over 13 years ago
Seyed Ehtesham Hasnain
Seyed Ehtesham Hasnain
Authorised Representative
over 19 years ago
Balasubramanian Dorairajan
Balasubramanian Dorairajan
Director/Designated Partner
almost 20 years ago

Past Directors

Appa Rao Podile
Appa Rao Podile
Director
over 8 years ago
Rammohan Rao Mendu
Rammohan Rao Mendu
Director
about 12 years ago
Goverdhan Mehta
Goverdhan Mehta
Additional Director
about 13 years ago
Sanyasa Apparao Thammineni
Sanyasa Apparao Thammineni
Additional Director
over 14 years ago
Bibhu Prasad Acharya
Bibhu Prasad Acharya
Additional Director
over 15 years ago
Sam Bob Busi
Sam Bob Busi
Additional Director
over 18 years ago
Venkateswarlu Akella
Venkateswarlu Akella
Whole Time Director
about 22 years ago
Anjireddy Kallam
Anjireddy Kallam
Director
about 22 years ago

Patents

An Improved Magnetic Nanoparticle Separating Device

An improved magnetic separator device for separation specific cell populations from mixture of cell comprises: a strong neodymium magnet (1) at the core, and embodied by a chemical inert translucent plastic material (5), four positions for holding four reaction tubes of different sizes; angular grooves (3), which ar...

An Artificial Dna Construct Having An Unique Bidirectional Genetic Promoter

An artificial DNA construct comprising a bidirectional promoter having a functional promoter (FS5), hybrid promoter (FUAS35SCP) at each end of the bidirectional promoter operably linked to a polynucleotide (gene) coding for a polypeptide (protein).

A Water Soluble Pegylated Pemetrexed & A Process For Preparing The Same

According to this invention, a process is provided for preparing a water soluble PEGylated pemetrexed comprising the amphiphilic polymer conjugated to the carboxylate form of pemetrexed. In accordance with this invention, the process provided for preparing PEGylated pemetrexed comprising of two steps. Initially,...

A Salicylic Acid Inducible Promoter Dna Fragment Obtained From Figwort Mosaic Virus Sub Genomic Transcript Promoter And A Method For Producing The Same

A salicylic acid inducible Figwort mosaic virus minimal promoter [FS-(TGACG)2] having an engineered 131 base pair ( -100 to + 31) showing enhanced root-activity was developed by inserting mutations at positions -84 (A→T) and -83(A→G) of the promoter.

Drug Delivery Formulation Of Rapamycin In The Form Of Polymeric Nanoparticles For Cancer Therapy

The present invention relates to a pharmaceutical composition of drug delivery polymeric nanoparticles for cancer therapy having absorption enhance & bioavailability promoter properties. The nanoparticles include a glyceryl monooleate, pluronic F-127, vitamin-E TPGS; and a cancer therapeutic agent, such as rapam...

A Water Soluble Polymeric Drug Formulation And A Process For Preparing The Same

A water soluble polymeric drug formulation and a process for preparing the same. According to this invention, there is provided a water soluble polymeric drug formulation comprising a water-soluble polymeric drug formulation comprising the amphiphilic polymer conjugated to the amino group of gemcitabine. In accorda...

Novel Compounds For Cancer Treatment

Novel indole compounds, their derivatives ,their analogs ,their tautomeric forms,their stereoisomers, their bioisosters, their diastereomers, their polymorphs, their enantiomers, their pharmaceutically acceptable salts, their pharmaceutically acceptable hydrates, their pharmaceutically acceptable solvates and phar...

A Full Length Transcript Promoter Dna Fragment From Dahlia Mosaic Virus

A genetic promoter DNA fragment (MTCC clone depositing no: 5884) obtained from Dahlia mosaic virus (DaMV), the genetic promoter is a 556 bp long full length transcript promoter (DaMV-FLt4, -474 to +82 from transcription start site) with enhanced activity.

Whole Cell Biosensor For The Detection Of Arsenic Contamination In The Drinking Water

Arsenic contamination in ground/drinking water is a serious concern in India. Continuous monitoring of ground water arsenic contamination is indispensable in prevention of arsenic poisoning. Attempts are being made worldwide to generate efficient and low cost biological solutions for detection of arsenic in the envi...

A Method For Enhancing Antimicrobial Activity Of Plant And Bacteria Derived Human Beta Defensin 1 (Hbd 1) And Human Beta Defensin 2 (Hbd 2).

A method for the production of human beta defensin 1 & 2 (HBD-1 and HBD-2) in plant and bacterial cells having antimicrobial activity comprising the steps of: molecular cloning of HBD-1 and HBD-2 in plant expression vector comprising efficient plant promoter, molecular cloning of HBD-1 & HBD-2 in bacterial expres...

A Novel Method Of Isolation Of Tlr4 From Cell Lysates Of Mononuclear Cells

A novel method of isolation of TLR4 from cell lysates of mononuclear cells comprising: collecting bovine adult filarial parasites (Setaria digitata); preparing aqueous extracts of setaria digitata (FAg) to produce affinity purified filarial glycoprotein (AgW); isolating human PBMCs from heparinised venous blood s...

Improved Process For The Preparation Of Dapagliflozin

The present invention relates to an improved process for the preparation of intermediate of dapagliflozin, a SGLT2 inhibitor used for the treatment of diabetes. The present invention further relates to process for the preparation of dapagliflozin.

Synergistic Pharmaceutical Co Crystals

The present invention discloses synergistic pharmaceutical co crystals comprising soluble forms of broad-spectrum fluoroquinolone antibacterial agents namely Ciprofloxacin and Norfloxacin with small molecules that have unique physical properties and biological activity which differ from the active agent in pure form...

Pharmaceutical Co Crystals Of Quercetin

Disclosed herein is synergistic pharmaceutical co-crystals composition comprising Quercetin and an antidiabetic agent(s) as combination drug that have unique physical properties and biological activity which differ from the active agent in pure form. The invention further discloses process for preparation of the sam...

A Method For Preparing A Water Dispersible Glyceryl Monooleate (Gmo) Magnetic Nanoparticle (Mnp) Formulation And Use Of The Same

The present invention is an aqueous dispersible magnetic nanoparticle formulation with a high drug loading capacity used for sustained drug delivery. The formulated magnetic nanoparticles are composed of an iron oxide core coated with a long chain polymer, which provides aqueous dispersibility without the use of s...

''A Novel Polymorph Of Catechin Hydrate"

Disclosed herein is highly soluble, thermally stable polymorphic form of Catechin hydrate which is characterized by PXRD, DSC, IR spectroscopy.

A High Througput Method For Detecting Apoptosis Of Embryonic Stages Of Metazoan Helminthic Parasites

A method for detecting apoptosis of embryonic stages of parasitic helminthes comprising: isolating of Intra Uterine embryonic stages from adult female parasite; culturing in vitro and treating said embryonic stages; subjecting the said embryonic stages to the step of flow cytometric analysis; developing assays for a...

A Genetically Modified Recombinant Rice Plant Catalase B, Expressed In E. Coli Host That Avoids Light And Temperature Impairment

A genetically engineered rice catalase-B from E.coli comprises antioxidant protein that can express in MIS strain of E.coli bacterial cytoplasm when coexist with bacterial chaperonin GroEL/ES wherein it is endowed with relatively higher resistance to elevated temperature treatment and is capable of functioning at hi...

A Sub Genomic Transcript Promoter Fragment From Dahlia Mosaic Virus

A genetic promoter DNA fragment (MTCC clone depositary no. 5883) obtained from Dahlia mosaic virus (DAMV), wherein the genetic promoter is a sub-genomic transcript promoter (DaMV– Sgt coordinates – 372 to +69) with enhanced activity.

A Novel Water Soluble Curcumin Loaded Nanoparticulate System For Cancer Therapy

The present invention provides a drug delivery system encompassing a water-insoluble drug curcumin for the treatment of cancer. The composition is containing a pharmaceutically acceptable carrier and thus providing a biocompatible drug delivery system. The invention further discloses the nanoparticles composed of...

A Process For Preparing Curcumin Encapsulated Chitosan Alginate Sponge Useful For Wound Healing

A process for preparing curcumin encapsulated chitosan alginate sponge comprising the steps of: incorporating curcumin in a fluid phase of oleic acid; subjecting the mixture to a step of emulsification with chitosan solution by homogenization; emulsifying the resultant solution with alginate solution by homogeni...

“A Method To Identify Circular Rna Splice Variants And Predict Their Functions”

The present invention relates to oligonucleotide primer sequences for the identification and amplification of full-length sequence of circular RNAs (circRNAs) comprising, a forward primer designed to identify and hybridize to the backsplice junction while the reverse primer is designed to hybridize to circRNA sequen...

Vascular Tissue Specific And Stress Inducible Hybrid Promoter Ideal For Plant Derived Pharmaceutical Production

Vascular tissue specific and stress inducible hybrid promoter ideal for plant derived pharmaceutical production. A vascular tissue specific and stress inducible hybrid promoter DNA fragment developed from the ligation of a upstream activation sequence of Figwort mosaic virus full length transcript promoter (FMV-F...

A Process For Characterization Of A Malarial Molecule Hmgb 1 For Developing An Anti Disease Vaccine.

The present invention discloses and claims a vaccine composition comprising principally of HMGB1 from Plasmodium falciparum (Pf HMGB1) and adjuvants for protection against respective malarial parasite. Further, the present invention claims a process for preparation of a vaccine composition against malaria comprising...

Preparation Of Novel 1 H Pyrazolo[4,3 D]Pyrimidines, Their Compositions, Synthesis And Methods Of Using Them For Treating Tuberculosis

The present invention provides novel heterocyclic compounds of Formula (I): their derivatives, analogs, tautomeric forms, stereoisomers, bioisosters, diastereomers, polymorphs, enantiomers, prodrugs and their pharmaceutically acceptable salts for the treatment of tuberculosis. Also disclosed is the process for prepa...

Griseofulvin As An Adjunct Drug For The Treatment Of Cerebral And Severe Malaria

Malaria remains a major concern of morbidity and mortality. Despite treating infected individuals with artemisinin-based combination therapies (ACTs), cerebral and severe malaria cause enormous mortality in children and adults. The only treatment option is parenteral administration of artemisinin or quinine with sup...

Composition For Enhancing Intra Cellular Nitric Oxide Generation

ABSTRACT COMPOSITION FOR ENHANCING INTRA-CELLULAR NITRIC OXIDE GENERATION The present invention discloses a pharmaceutical composition comprising 1-{3-[9-methoxy-7-(2-methoxyphenyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-4-carbonyl]phenyl}imidazolidin-2-one ; N-tert-butyl-2-{N-[(furan-2-yl)methyl]-2-[5-(4-methyl...

A 3 D Extracellular Matrix Scaffold And Method Of Preparation Thereof

ABSTRACT A 3D-EXTRACELLULAR MATRIX SCAFFOLD AND METHOD OF PREPARATION THEREOF The present disclosure relates to a 3D-extracellular matrix scaffold and uses thereof as bone graft substitute. The 3D-extracellualr matrix comprises a porous polymer scaffold and pre-differentiated osteoblast derived exosomes. The pres...

A Live Attenuated Vaccine Against Candida Albicans And A Method Thereof

ABSTRACT A LIVE ATTENUATED VACCINE AGAINST CANDIDA ALBICANS AND A METHOD THEREOF The present disclosure related to a live attenuated whole cell vaccine against a fungal pathogen C. albicans, wherein vaccine comprises a genetically engineered live attenuated strain of C. albicans the target gene POL32 has been ...

A Disposable Isolator Bag For In Vivo Imaging Of Small Animals In A Biocontainment Facility

A disposable isolator bag (102) used for in vivo imaging in a micro CT system is disclosed. The disposable isolator bag (102) includes an inflatable enclosed chamber (104) having a first side (104a), a second side (104b) opposite to the first side (104a), a base surface (104d) and an upper surface (104c) opposite to...

A Pharmaceutical Composition To Combat Artemisinin Resistance In Malaria

The present disclosure relates to a pharmaceutical composition to combat artemisinin resistance in malaria with the identification of Plasmodium falciparum (Pf) glutamine synthetase (GS) as a drug target. Pf GS is important for maintaining asparagine levels in the parasite and promote protein synthesis. Since ART-re...

Generation Of A Genetically Engineered Live Attenuated Candida Albicans Strain

ABSTRACT GENERATION OF A GENETICALLY ENGINEERED LIVE ATTENUATED CANDIDA ALBICANS STRAIN The invention discloses a genetically modified Candida albicans strain CNA94, wherein the strain is a genes knockout strain. The invention also discloses a method of genetically engineering double gene knockouts in Candida...

A Thermoresponsive Hydrogel And A Method Of Preparation Thereof

The present invention discloses a thermoresponsive hydrogel comprising: a protein component; and a polymer component; wherein the protein component is a mucoadhesive protein and/or collagen; and the protein is cross linked with a polymer, to form a protein-polymer solution that undergoes phase transition from sol-to...

Cocrystal Of Telmisartan And Ascorbic Acid, Composition Comprising Same And Method Of Use

As Attached

Composition For Enhancing Intra Cellular Nitric Oxide Generation

The present invention discloses a pharmaceutical composition comprising 1-{3-[9-methoxy-7-(2-methoxyphenyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-4-carbonyl]phenyl}imidazolidin-2-one ; N-tert-butyl-2-{N-[(furan-2-yl)methyl]-2-[5-(4-methylphenyl)-2H-1,2,3,4-tetrazol-2-yl]acetamido}-2-(4-hydroxyphenyl)acetamide ; 3-[2-...

A Protein Subunit Vaccine Composition Against Mycobacterium Tuberculosis

The present invention relates to an antigenic protein and a vaccine composition against Mycobacterium tuberculosis. The antigenic protein is a C-terminal truncated Hsp16.3 protein of Mycobacterium tuberculosis (Hsp16.3ΔC4). The present invention also provides a process for the preparation of antigenic protein. ...

A Formulation To Inhibit The Growth Of Multidrug Resistance S. Aureus

The present invention relates to a formulation to inhibit the growth of multidrug resistance S. aureus. More particularly, the formulation characterised with Montelukast as an inhibitor of efflux pumps in multidrug-resistant staphylococcus aureus that lowers the operating and capital costs associated with developing...

Pharmaceutical Composition For Inhibition Of Dna Polymerase Kappa (Pol K)

The present invention relates to a pharmaceutical composition comprising 2-(2- chlorophenyl)-5-[6-phenoxy-4-(trifluoromethyl) pyridin-3-yl]-1,3,4-oxadiazole and MgCl2 as a DNA Polymerase Kappa inhibitor, methods of preparing them, and methods of treatment, prevention, and amelioration of DNA Polymerase Kappa-based ...

Charges

0
25 February 2013
Axis Bank Limited
1 Crore
03 November 2005
Icici Bank Ltd.
5 Crore
01 September 2010
State Bank Of Hyderabad
2 Crore
01 September 2010
State Bank Of Hyderabad
0
03 November 2005
Icici Bank Ltd.
0
25 February 2013
Axis Bank Limited
0
01 September 2010
State Bank Of Hyderabad
0
03 November 2005
Icici Bank Ltd.
0
25 February 2013
Axis Bank Limited
0
01 September 2010
State Bank Of Hyderabad
0
03 November 2005
Icici Bank Ltd.
0
25 February 2013
Axis Bank Limited
0

Documents

Form MGT-7-09102020_signed
List of share holders, debenture holders;-08102020
Form AOC-4-11092020_signed
Directors report as per section 134(3)-10092020
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-10092020
Details of salient features and justifications for entering into Contracts/Arrangements/Transactions with related parties as per section 188 (1) - Form AOC - 2-10092020
Form DPT-3-13082020-signed
Form DPT-3-11042020-signed
List of share holders, debenture holders;-10102019
Form MGT-7-10102019_signed
Form ADT-1-10092019_signed
Details of salient features and justifications for entering into Contracts/Arrangements/Transactions with related parties as per section 188 (1) - Form AOC - 2-10092019
Copy of written consent given by auditor-10092019
Copy of the intimation sent by company-10092019
Directors report as per section 134(3)-10092019
Optional Attachment-(1)-10092019
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-10092019
Copy of resolution passed by the company-10092019
Declaration of the appointee director, Managing director, in Form No. DIR-2;-10092019
Form DIR-12-10092019_signed
Form AOC-4-10092019_signed
Form DPT-3-28062019
Form MSME FORM I-09062019_signed
Optional Attachment-(1)-02032019
Declaration of the appointee director, Managing director, in Form No. DIR-2;-02032019
Form DIR-12-02032019_signed
Interest in other entities;-02032019
List of share holders, debenture holders;-05102018
Form MGT-7-05102018_signed
Form MR-1-26092018-signed